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nents of the NVU, e.g., astrocytes and pericytes, to the main-
tenance of this physiological barrier. We also explore the 
development of therapeutic options in HIE, such as harness-
ing the transport systems in the BBB, to enable the delivery 
of large molecules with molecular Trojan horse technology, 
and the reinforcement of the physical barrier with cell-based 
therapy which utilizes endothelial progenitor cells and stem 
cells.  © 2017 S. Karger AG, Basel 
 Introduction 
 The unifying disturbance to neural tissue in hypoxic-
ischaemic encephalopathy (HIE) is a deficit in oxygen 
supply  [1] . This can occur because of hypoxia, a dimin-
ished amount of oxygen in the blood supply, and isch-
aemia, a diminished amount of blood perfusing the brain. 
It is important to recognize that the resulting damage to 
the brain tissue continues to develop hours to days after 
the initial HI episode in term newborns  [2–4] . Northing-
ton et al.  [5] propose the concept of “continuum in cell 
death,” whereby the degeneration of neurons lies along a 
continuum between apoptosis and necrosis. This concept 
emphasizes the variety of mechanisms of injury and the 
complex cellular interactions that occur in response to it, 
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 Abstract 
 This review aims to highlight a possible relationship be-
tween hypoxic-ischaemic encephalopathy (HIE) and the dis-
ruption of the blood-brain barrier (BBB). Inflammatory reac-
tions perpetuate a large proportion of cerebral injury. The 
extent of injury noted in HIE is not only determined by the 
biochemical cascades that trigger the apoptosis-necrosis 
continuum of cell death in the brain parenchyma, but also 
by the breaching of the BBB by pro-inflammatory factors. We 
examine the changes that contribute to the breakdown of 
the BBB that occur during HIE at a macroscopic, cellular, and 
molecular level. The BBB is a permeability barrier which sep-
arates a large majority of brain areas from the systemic cir-
culation. The concept of a physiological BBB is based at the 
anatomical level on the neurovascular unit (NVU). The NVU 
consists of various cellular components that jointly regulate 
the exchanges that occur at the interface between the sys-
temic circulation and the brain parenchyma. There is in-
creased understanding of the contribution of the compo-
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which ultimately contribute to cell death. After the rela-
tive success of translating mild therapeutic hypothermia 
from the bench to the bedside for neuroprotection, ad-
junctive treatments which aim to further increase neuro-
protection are undergoing exploration.
 In this paper, we review the relationship between HIE 
and the blood-brain barrier (BBB). More than just being 
a physical barrier formed by tight junctions between the 
endothelial cells, the BBB is a dynamic physiological bar-
rier which regulates the passage of hydrophilic molecules 
into the central nervous system (CNS) via transporters 
and enzymes  [6–9] . There is active communication be-
tween endothelial cells, pericytes, astrocytes, microglia, 
the structural basement membrane, and the extracellular 
matrix (ECM), which is vital for the modulation and the 
maintenance of the selective permeability of the BBB. 
Perivascular macrophages, which are adjacent to endo-
thelial cells immediately beyond the basement mem-
brane, also have a regulatory role. This complex system is 
referred to as the neurovascular unit (NVU)  [10, 11] , and 
it underlies the BBB function by acting as an exchange 
interface between the blood and the CNS. It enables the 
CNS environment to remain stable despite fluctuations in 
the composition of plasma and brain interstitial fluid, 
thus preventing interference with signal transmission. 
The progress in the characterization of the BBB structure 
through proteomics  [12] and the improvement in drug 
delivery by taking advantage of the endogenous trans-
porting systems of the BBB  [13, 14] hint at the potential 
of the BBB to take a more prominent role in our under-
standing and management of HIE. However, this discus-
sion also serves to highlight the challenges and controver-
sies in our understanding of the BBB and its relationship 
to HIE. The observations discussed in this review origi-
nate from a variety of experimental models (summarized 
in  Table 1 ).
 Defining the Blood-Brain Barrier by Its Morphology 
and Function 
 A cross-section of the NVU can be visualized as a lay-
er of endothelial cells and interconnected junctional-pro-
tein complexes surrounded on the outside by a basement 
membrane which is shared with enveloping pericytes. 
Perivascular macrophages abut endothelial cells. Beyond 
the basement membrane, astrocytic end feet are in direct 
communication with the vascular lining and thus act as a 
cellular link with neurons, all of which are anchored in 
place by ECM proteins  [6] . The significant restriction of 
passage of substances across the BBB is reflected in the 
high trans-endothelial electrical resistance (TEER) across 
the endothelial cells of the BBB, which is 50 times higher 
than that across the peripheral endothelium  [15] . One of 
the main physical characteristics of the brain endothelial 
lining, underpinning its barrier function, lies in the com-
plex tight junctions which limit the intercellular move-
ment of molecules  [7] . Amongst the proteins making up 
this structure are the transmembrane proteins occludin 
and claudin  [16] . There is evidence that claudins contrib-
ute to the high TEER across the BBB  [7] , and claudin-5 
shows promise as a therapeutic target as BBB permeabil-
ity to small molecules of a molecular weight of <800 Da 
increases in its absence  [17] . The role of other proteins, 
including zonula occludens proteins (ZO-1, ZO-2, and 
ZO-3), which anchor the tight junctions to the cellular 
cytoskeleton, and junctional-adhesion molecules (JAM-
A, JAM-B, and JAM-C), which help regulate the tightness 
of the junctions, is not as well understood and requires 
further work  [18] .
 The Role of Pericytes 
 Platelet-derived growth factor BB (PDGF-BB), secret-
ed by the endothelial cells, forms a concentration gradient 
at the basement membrane and recruits pericytes to take 
up their position  [19] . Pericytes reinforce and support the 
NVU; in their absence, microaneurysms form and there 
is rupture of the microvascular structures  [20, 21] . Peri-
cytes may be important in determining BBB permeability, 
by inhibiting the expression of molecules promoting vas-
cular permeability and immune cell infiltration. Pericytes 
regulate functional aspects of the BBB, including the for-
mation of tight junctions and vesicle trafficking in CNS 
endothelial cells  [22] .
 The Role of Astrocytes 
 The role of astrocytes in the BBB is less certain and is 
more controversial  [23–25] . Studies using immunohisto-
chemistry and co-cultures of astrocytes with endothelial 
cells and pericytes show that astrocytes are necessary to 
guide interactions between these cells, and their presence 
contributes to the upregulation of BBB properties in the 
endothelial lining  [26] . It has been postulated that be-
cause astrocytes appear in development after the vascu-
larization of the brain, this emphasizes their “mainte-
nance” and supportive role. 
 The Role of CNS Mononuclear Phagocytes 
 Microglia are the most abundant myeloid cell popula-
tion in the CNS. Determining the origins of microglia has 
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 Table 1.  Summary of studies on the BBB and the models on which they were based
First author [Ref.], year Experimental model
Colbourne [3], 1995 15-week-old gerbils; temporary occlusion of carotid arteries
Geddes [4], 2016 P7 rats; carotid artery ligation and hypoxia
Butt [15], 1990 infant and fetal rats (age range: 17 gestational days to P33); hyperosmotic shock and metabolic poisons
Nitta [17], 2003 genetically modified claudin-5-deficient newborn mice
Lindahl [20], 1997 PDGFB-deficient mouse embryos
Tallquist [21], 2003 PDGFR-β allelic variants – mouse embryos
Janzer [24], 1987 neonatal rat astrocytes and meningeal cells
Ramsauer [26], 2002 astrocytes from rats aged 8 – 12 weeks and 1 – 2 days; endothelial cells and pericytes
He [29], 2016 mice aged 8 – 12 weeks
Wang [30], 2012 genetically modified mice (Frizzled signalling) ranging from newborns to adults
Liebner [31], 2008 genetically modified mice (Wnt signalling) ranging from embryonic to early postnatal mice + young 
adult mice endothelial cell culture
Alvarez [32], 2011 human BBB endothelial cells + genetically modified mice (Hedgehog signalling) ranging from 
embryos to adults
Haqqani [36], 2013 immortalized human brain microvascular endothelial cells
Grontoft [37], 1954 post-mortem of legally aborted human and rabbit fetuses
Dziegielewska [38], 1979 fetal sheep; early and late gestation permeability studies
Ek [40], 2015 P9 mice; HI model
Muramatsu [41], 1997 P7, P14, and P21 rats; HI model
Chen [42], 2012 fetal sheep ischaemia model
Chen [43], 2006 mammalian cancer cells
Baskaya [44], 1997 adult rats; traumatic brain injury
Kumar [45], 2008 term neonates; HIE
Kotter [49], 2006 adult rats; demyelination model
Ritzel [52], 2015 mice aged 10 – 12 weeks; middle cerebral artery occlusion
Hu [53], 2012 mice aged 10 – 12 weeks; focal transient cerebral ischaemia + embryonic rat cell culture 
Breckwoldt [54], 2008 adult mice; unilateral middle cerebral artery occlusion
Gliem [55], 2012 mice aged 6 – 10 weeks; photothrombosis and transient middle cerebral occlusion
Chu [56], 2015 mice aged 8 – 12 weeks; occlusion of the middle cerebral artery
Crane [57], 2014 mouse aged 8 – 10 weeks; sterile wound model
Noda [58], 2011 mouse embryonic neuronal and microglial cells
Elliott [59], 2009 mice aged 8 – 12 weeks; murine air pouch model, mouse aged 4 – 5 weeks; thymic clearance model 
Feng [62], 2008 P7 rats; HIE
Schmid-Brunclik [63], 2008 newborn rat astrocytes
Wang [64], 2001 brain microvessel endothelial cells from bovine grey matter
Kaur [65], 2006 adult rats; hypoxia model
Chen [67], 2008 P7 rats; HI model
Sheldon [68], 2009 P7 mice; hypoxia and HI model
Nedelcu [69], 1999 P7 rats; HI model
Manley [74], 2000 adult mice; AQP4 deficient and middle cerebral occlusion
Fu [76], 2007 P3 rat astrocytes
Heo [78], 1999 adolescent baboons; middle cerebral artery occlusion
Shankaran [80], 2005 newborns (at least 36 weeks’ gestational age); HIE
Azzopardi [81], 2009 newborns (at least 36 weeks’ gestational age); perinatal asphyxia
Baumann [82], 2009 adult rats; bilateral common carotid artery occlusion
Jurkovich [83], 1988 cat intestine; ischaemia model
Boado [86], 2010 adult rhesus monkey; BBB and fusion protein studies
Boado [87], 2010 adult rhesus monkeys; BBB and fusion protein studies
Zhou [89], 2011 adult mice; 6-hydroxydopamine model of Parkinson disease
Sumbria [90], 2012 adult mice; reversible middle cerebral artery occlusion 
Sumbria [91], 2013 adult mice; reversible middle cerebral artery occlusion
Liao [92], 2013 neonates with HIE and children with cerebral palsy
Asahara [94], 1997 human endothelial progenitor cells; rabbit and mouse ischaemia models
Peichev [95], 2000 human fetal liver cells and cord blood cells
Zhang [97], 2002 adult mice; middle cerebral artery occlusion
Fan [99], 2010 adult mice; transient middle cerebral artery occlusion
Ohta [100], 2006 rats aged 8 – 10 weeks; middle cerebral artery occlusion
P, postnatal day. 
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been challenging due to their unique characteristics as 
both glial cells involved in regulating synaptic structures 
and immune cells surveying and responding to injury. 
Microglia are derived from haematopoietic stem cells in 
the yolk sac, differing thus from peripheral macrophages, 
which are derived from the bone marrow  [27] . Embry-
onic microglia actively proliferate, maintaining a steady-
state supply into adulthood, without a contribution from 
peripheral monocytes. Microglia are present in the CNS 
prior to the endothelial presence, and it has been sug-
gested that the interaction between microglia and endo-
thelium plays a key role in BBB formation and function. 
Changes in equilibrium associated with injury, however, 
result in the recruitment of peripheral monocytes which 
are able to differentiate into cells with properties similar 
to those of microglia (also called monocyte-derived mac-
rophages, MDMs). The contribution of the embryonic or 
peripheral MDMs to the acute and chronic phases of HI 
injury has yet to be fully established.
 Other mononuclear phagocytes that exist in the CNS, 
e.g., the perivascular macrophages which contribute to 
the NVU, have less well-defined roles. They originate 
from the bone marrow and reside in closer communion 
with the vasculature as opposed to the microglia, which 
infiltrate the CNS tissue  [28] . A recent study  [29] has re-
vealed that communication with endothelial cells appears 
to promote polarization of the perivascular macrophages 
to exhibit an M2 phenotype (a concept discussed later). 
Indeed, it appears that only peripheral monocytes ex-
pressing genes favouring differentiation to the M2 phe-
notype are able to reconstitute previously disrupted BBB 
permeability. Furthermore, similarly to pericytes, peri-
vascular macrophages can dissociate from the vascula-
ture and contribute to the increased permeability of a dis-
rupted BBB  [29] .
 The BBB as a Dynamic Barrier 
 The brain endothelial cells express BBB-specific genes 
that enable the development of the endothelial barrier in 
the absence of external influences. However, pericytes, 
astrocytes, perivascular macrophages, and microglia may 
still have a role to play in regulating and maintaining the 
functional characteristics of the BBB after the formation 
of the endothelial barrier. Recent studies show that the 
BBB is not an unassailable structure and that removal of 
the interdependent components of the NVU can result in 
the loss of its barrier properties  [30–32] .
 The BBB is a functionally dynamic construct. For ex-
ample, endothelial dysfunction is associated with the re-
lease of microparticles such as endothelial microvesicles 
and exosomes. These particles contain mixtures of pro-
teins and other components, which are shared with the 
parent cell  [33] . They have a diverse profile of adhesion 
molecules, antigen-presenting molecules, and other pro-
teins involved in cell-to-cell signalling, and have been a 
recent focus of interest for their proposed role in the cel-
lular and BBB trafficking of molecules  [34] . Particularly 
of interest is their specificity and sensitivity as biomarkers 
of the involvement of the BBB in neurological pathologies 
that can be detected peripherally, as they are extruded 
from the brain endothelial cells into the bloodstream
 [35, 36] .
 Maturation of the BBB 
 The developmental changes in BBB morphology and 
function are not fully understood and much of our cur-
rent understanding of the effect of hypoxia on the cere-
bral vasculature is derived from adult models.
 In 1954, Grontoft et al.  [37] demonstrated that the BBB 
obtained from legally aborted human fetuses was imper-
meable to Trypan blue dye as early as at the point of pla-
centa separation. Their interpretation of this observation 
was that a functional BBB was already present at the fetal 
stage of human development. In addition, brain staining 
was noted to occur when some time had elapsed after pla-
cental separation. This was postulated, and later con-
firmed, to be the effect of hypoxia on the permeability of 
the BBB  [23] . There is evidence that the fetal and newborn 
BBB may indeed be functional, at least in lower species; 
immunostaining reveals evidence of a functionally intact 
BBB in rats as early as embryonic day 16 (E16)  [23] .
 In E60 fetal sheep, Dziegielewska et al.  [38] noted that 
the intravascular injection of Alcian blue had reached the 
brain tissue, not through the tight junctions, which were 
observed to be well formed by E60, but via intracellular 
vesicles, with declining activity by E125. Thus, the idea 
was conceived of the earlier maturation of tight junctions, 
followed by the maturation of transcellular transport in 
the developing BBB. These 2 mechanisms have been pro-
posed to become fully functional at different points along 
the timeline of development.
 The Effects of HI Injury on the BBB 
 Important effects of HI injury on the BBB include an-
giogenesis and changes in permeability. Several key mol-
ecules have a role in angiogenesis, including hypoxia-
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inducible factor-1 (HIF 1α ), vascular endothelial growth 
factor (VEGF) and erythropoietin. Angiogenesis can be 
divided into 2 processes: angiogenic remodelling and an-
giogenic sprouting  [39] . The latter involves the replace-
ment of old vessels, which are broken down, with new 
immature vessels, leaving the BBB vulnerable to oedema-
tous disruption and mechanical stress. This is in com-
parison to the former, whereby existing vascular net-
works undergo changes leading to the development of a 
mature, stable vasculature contributing to the BBB.
 BBB permeability has been measured by various meth-
ods and the models used to study permeability in re-
sponse to HI insult have been diverse. There is consensus 
that there is an increased early BBB permeability, peaking 
at between 2 and 4 h after insult in most neonatal injury 
models ( Table 2 )  [40–42] .
 In the neonatal injury models, there is less compelling 
evidence of a delayed second phase of increased BBB per-
meability, which has been noted in the adult rat model 
 [43, 44] . The BBB in human babies with HIE shows in-
creased permeability as assessed by comparing the con-
centrations of albumin in cerebrospinal fluid (CSF) ver-
sus plasma  [45] . Equally as important, this study also 
lends support to the proposed relationship between HIE 
and the BBB, suggesting free radical injury as an amplifi-
cation factor in the pathophysiological processes of both 
HIE and BBB dysfunction.
 Whether or not the BBB experiences a second phase of 
increased permeability after HI injury, there is early acti-
vation of mechanisms that lead to the eventual restora-
tion of BBB function after the insult, as demonstrated by 
the observation of an upregulation in the transcription 
and expression of tight-junction proteins in the neonatal 
mouse and the fetal sheep model  [40, 42] .
 The Effects of HI Injury on the Cellular Components 
of the NVU 
 Engelhardt et al.  [46] demonstrated that the endothe-
lial cells are more susceptible to hypoxia-induced injury, 
as seen by a disruption in their cellular cytoskeleton struc-
ture, than pericytes and astrocytes which retain the cyto-
skeleton arrangement even with prolonged hypoxia. This 
was discussed in the context of the oxygen concentration 
these cells are exposed to in the normal brain environ-
ment, whereby astrocytes and pericytes occupy areas ex-
posed to lower oxygen concentrations than the endothe-
lial cells. The case becomes more complex when it is not-
ed that the proliferation of pericytes and astrocytes is 
downregulated when exposed to hypoxia whereas endo-
thelial cells continue to proliferate despite this being 
counterproductive to the conservation of energy and, ul-
timately, their survival. For endothelial cells, this is fur-
ther associated with a rapid induction of the HIF 1 protein 
and BBB disruption.
 Microglia are the first immune cells of myeloid origin 
to respond to signals of inflammation such as damage-
associated molecular patterns (DAMPs) released from 
damaged tissue  [47] . Their role remains controversial. 
Microglia may also have a neuronal protective role against 
toxicity associated with stimulation of the NMDA gluta-
mate receptors, as demonstrated by studies introducing 
microglia to previously microglia-free, organotypic slice 
cultures  [48] .
 Microglia phagocytic activity removes cell debris, 
which is crucial to set the stage for axonal regeneration 
and structural remodelling of neural networks; myelin 
remnants may contribute to disruption of remyelination 
due to the release of growth inhibitors  [49] . Furthermore, 
 Table 2.  Summary of studies on the timeline of BBB permeability changes after HI injury
First author 
[Ref.], year
Animal 
model
Age Measured indicator of BBB
permeability
Earliest peak
of BBB
permeability
Sampling time
after HI injury
Muramatsu
[41], 1997 
rat postnatal day 7 IgG immunoreactivity 6 h 3, 6, 9, 12, 18, and 24 h
Chen
[42], 2012 
sheep 125 – 129 gestational days 
(85 – 87% of
gestation)
calculation of blood-to-brain
transfer constant for
radioactive tracer 
4 h 4, 24, and 48 h
Ek
[40], 2015 
mouse postnatal day 9 CSF-to-plasma sucrose
concentration ratio and
albumin immunoreactivity
2 h 2, 6, 24, and 72 h
(and 168 h for sucrose 
concentration ratio)
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their clearance is influenced by the presence of pro-
inflammatory cytokines such as TNFα, which have been 
shown to reduce the phagocytic activity of macrophages 
 [50] .
 In parallel to the T helper 1 (Th1)/Th2 polarization 
concept relevant to T cells, macrophages may also be dif-
ferentiated into an M1/M2 phenotype  [51] , an oversim-
plified concept that extends to the microglia as well. M1 
macrophages, which are pro-inflammatory, contribute to 
generating free radicals and matrix metalloproteinase 
(MMP)9-mediated injury  [47] . M2 macrophages pro-
mote the resolution of the inflammatory phase and its 
subsequent transition to healing and repair. In the pres-
ence of ischaemia, microglia and MDMs seem to favour 
differentiation into the M1 phenotype  [52] , which is as-
sociated with worse oxygen-glucose deprivation (OGD)-
induced neuronal loss  [53] . Peripheral monocytes re-
spond relatively later than microglia, i.e., on days 3–7 af-
ter ischaemic stroke  [54] ; those expressing genes favouring 
conversion to the M1 phenotype arrive earlier than those 
expressing genes favouring M2 polarization. Though 
their pro-inflammatory repertoire seems an obvious 
threat to mounting injury, their presence has been shown 
to be vital to the damage control of the ischaemic injury 
 [55] . This may be explained by their ability to influence 
surrounding microglia/MDMs to convert into M2 phe-
notype macrophages  [56] in addition to their own sub-
sequent conversion to M2 phenotype macrophages. The 
players controlling the switch from the inflammatory 
phase to the repair phase, though yet to be defined, are 
probably a combination of factors. Firstly, M1 macro-
phages release TGFβ and VEGF once in the area of injury 
 [57] . Secondly, dying cells release CX3CL1, which attracts 
M2 macrophages, mainly since they have a higher level of 
expression of corresponding receptors  [58–60] . Both of 
these are associated with wound healing and tissue re-
modelling.
 The Role of VEGF 
 Not only are the pericytes and astrocytes better able to 
adapt to the HI insult, they have also been shown to be 
vital in reducing injury through the secretion of protec-
tive factors, such as VEGF. VEGF exists as a family of 6 
homologous members: VEGF-A, -B, -C, -D, and -E, as 
well as placental growth factor  [61] . They bind to tyrosine 
kinase receptors known as VEGF receptors, and are 
prominently involved in coordinating the development 
and regulation of blood vessels. The protective role of 
VEGF lies in increasing the survival of endothelial cells 
and reducing the volume of infarcted tissue via the inhibi-
tion of apoptotic mechanisms  [62, 63] .
 However, VEGF contributes at the same time to in-
creased BBB permeability via the destabilization of junc-
tional proteins, including the tight junctions and adher-
ens junctions  [64] . This leads to vasogenic oedema, and 
may provide the link between increased BBB permeabil-
ity and the pathophysiological inflammation in HIE  [65] . 
Due to the diversity of the VEGF family, it is possible that 
the conflicting roles of VEGF following HI brain injury 
can be explained by the interactions between the different 
forms of VEGF and their corresponding receptors.
 One of the important contributors to VEGF upregula-
tion is HIF 1α  [66] . Hypoxia initiates the activation of this 
factor, resulting in the expression of genes responsible for 
angiogenesis. Similar to VEGF, Baburamani et al.  [39] re-
port conflicting effects of HIF 1α subsequent to HI insult 
and suggest that time post-injury is a determining factor. 
Acutely, the absence of HIF 1α has been associated with a 
reduced degree of injury  [67] . Over a longer time course, 
however, mice unable to express HIF 1α were found to 
have a worse outcome than wild-type controls  [68] .
 A Reversal of Roles: Impact of BBB Dysfunction on 
the Pathophysiology of HIE 
 Ek et al.  [40] have shown a correlation between areas 
of disrupted BBB function and areas of infarction in the 
brain. Nedelcu et al.  [69] noted that a moderate HI insult 
in the brain of postnatal day 7 (P7) rats produced a first 
phase of cytotoxic oedema, which was followed 4 h later 
by a second wave of cytotoxic oedema and new develop-
ment of vasogenic oedema. Cerebral vasogenic oedema 
develops in the presence of increased BBB permeability, 
allowing for an unregulated accumulation of water con-
tent in brain tissue  [70] .
 The expression of aquaporin 4 (AQP4), the major wa-
ter channel of the mammalian brain  [71] , appears to be 
concentrated at the end-feet of the astrocytic component 
of the NVU  [72] . AQP4 does not act solely as a regulator 
of water flow, it also serves other physiological functions 
 [73] . AQP4 may control the flow of water bidirectionally, 
due to the observation that its absence can have 2 oppos-
ing outcomes in different types of pathology  [74, 75] . The 
absence of AQP4 reduces the severity of the oedema dur-
ing the acute phase of HI injury. However, when oxygen-
ation is reintroduced, the absence of AQP4 results in a 
longer time taken to clear the excess water  [76] .
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 The increase in BBB permeability may contribute to 
HI injury of the brain through the increased exposure of 
brain tissue to inflammatory mediators. One of the down-
stream pathways linked to TNFα, which is released in 
HIE, involves the activation of MMPs  [77] . These proteo-
lytic enzymes, especially MMP3 and MMP9, have been 
implicated in BBB disruption due to proteolysis of ECM 
proteins and cleavage of tight junctions, resulting in oe-
dema and haemorrhage  [78, 79] . Therapeutic hypother-
mia (TH) is the only effective treatment in clinical use at 
present that intervenes at the level of the pathological 
mechanisms of HIE. In the clinical setting, TH has been 
shown to be effective when commenced within 6 h after 
birth  [80, 81] . From the point of view of the BBB, TH has 
been shown to reduce the activity of enzymes, especially 
that of MMPs, as well as maintain ECM molecular and 
cellular integrity  [82, 83] .
 Exploitation of Molecular Exchanges across the 
BBB to Increase Drug Delivery to Injured Brain 
Parenchyma 
 An early increase in BBB permeability has been noted 
after HI insult, and we also know that neuroprotective 
interventions are more likely to be effective if commenced 
early. Therefore, we may postulate there to be a time win-
dow, as yet not clearly defined, in which effective drug 
delivery through the BBB may optimally exert a protec-
tive effect. The second concept is the targeting of changes 
in the BBB and how we can modulate these in an attempt 
to repair the injury caused in HIE.
 The BBB has, at times, been mistakenly regarded as 
one and the same as the blood-CSF barrier  [84] . While 
the BBB is spread across the capillaries of the brain, the 
blood-CSF barrier is focused at the choroid plexus in the 
ventricles. In the attempts to overcome the restrictions of 
the BBB, the solution of utilizing the blood-CSF barrier 
for the delivery of drugs into the intrathecal compart-
ment was developed. However, this mode of delivery is 
limited by differentials in diffusion rates; diffusion from 
the CSF into the bloodstream is faster than direct diffu-
sion from the CSF into brain tissue, so, paradoxically, 
drugs introduced into the CSF compartment are more 
likely to reach the brain parenchyma via the bloodstream 
and across the BBB, rather than directly by passage into 
the brain tissue.
 MTH Technology: The Potential Role of 
Carrier-Mediated and Receptor-Mediated 
Transporters 
 The BBB has been considered as the single most im-
portant limiting factor in the development of neurother-
apeutic drugs  [13] . This is partly because reliance on 
high-throughput screening (HTS) is more likely to select 
molecules of high molecular weights. Hydrophobic mol-
ecules with a molecular weight of <400 Da cross the BBB 
by free diffusion, while hydrophilic and large molecules 
gain access either via the carrier-mediated or receptor-
mediated transport (RMT) system  [84] .
 These systems transport molecules which retain the 
generic structures of the original substrates which the car-
riers and receptor transporters recognize as their target. 
This concept has led to the utilization of the intrinsic 
mechanism of the BBB to enable drug delivery in the form 
of molecular Trojan horse (MTH) technology. This relies 
on combining biologic therapeutics with monoclonal
antibodies (MAbs, which are specific for receptors across 
the BBB), which take up substances from the periphery 
via RMT systems, such as insulin and transferrin  [14, 85] . 
Two of these genetically engineered MAbs are fusion pro-
teins with IgG portions targeted against the human in-
sulin receptor (HIR) and transferrin receptor (Tfr), i.e., 
HIRMAb and TfrMAb  [85] .
 At present, all the evidence for the effectiveness of this 
technology is extrapolated from adult models. The final 
consensus on the functional maturity of the BBB in the 
fetus and the newborn has not been reached. On an opti-
mistic note, inward transport, including the RMT for 
transferrin, across the BBB has been shown to function in 
the fetal and newborn brain  [23] .
 The utility of MTH has enabled large molecules such 
as TNFα inhibitors  [86] and erythropoietin  [87] to be de-
livered across the BBB. We use these examples as agents 
being investigated for the treatment of HIE  [88] . They 
have been shown to fulfil several criteria for effective 
MTH technology, including having a higher affinity of 
the fusion protein than the MAb only for its target  [89] as 
well as having a higher uptake across the BBB via a high-
er affinity for the specific RMT system  [86] .
 Most studies of MTH technology have focused on the 
effect of these fusion proteins in adult models of acute 
stroke when assessing the impact on pathology, and they 
have demonstrated a reduction in infarct volume  [90, 91] . 
Given that a number of the pathophysiology mechanisms 
are the same as those seen in stroke provides hope that 
this technology may be applicable not just to HIE but also 
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neonatal encephalopathy from other causes. These stud-
ies await translation from the laboratory models to the 
clinic.
 Stem Cell Therapy 
 Another exciting innovation that builds upon the con-
cepts of the synergy of action between the different cells 
of the NVU is cell-based therapy. While deriving new 
cells from stem cells and progenitor cells is surrounded 
by much controversy, it remains, in theory, an attractive 
proposal for the repair and prevention of further injury 
to the brain. Cell-based therapies can be derived from 
various sources including umbilical cord blood, bone 
marrow, embryonic nervous tissue, and even adult brains 
 [92] . Of interest in the BBB and indeed the nervous sys-
tem, stem cells from umbilical cord blood are considered 
to be advantageous because they are a rich source of
endothelial progenitor cells (EPCs)  [93] , cells which have 
just begun to change our understanding of vascular de-
velopment, injury, and repair.
 EPCs are a population of stem cells which are activated 
and recruited from sources including the bone marrow, 
umbilical cord blood, and peripheral blood, in reaction to 
hypoxia  [94, 95] . Their discovery led to the new concept 
of vasculogenesis  [96] ; this is the development of new 
blood vessels by the recruitment and maturation of EPCs, 
in contrast to angiogenesis whereby new blood vessels are 
formed from proliferation of the pre-existing endotheli-
um. Thus, it was hypothesized that harnessing the poten-
tial of EPCs in promoting neovascularization in the pres-
ence of ischaemic injury  [97] would be valuable as a nov-
el therapeutic intervention  [98] . Indeed, several studies 
which have begun to assess the impact of the activation of 
EPCs in the presence of ischaemic injury have demon-
strated that EPC treatment reduces infarct volume, im-
proves deficits in cognitive learning and motor skills, and 
is associated with the recovery of regional cortical blood 
flow  [99, 100] .
 However, as a note of caution: EPC treatment has been 
linked with the production of nitric oxide and VEGF 
 [101] . While the properties of EPCs as growth factors and 
vasodilators may contribute to the restoration of blood 
flow to the ischaemic regions, a consensus on the effect of 
restoring cerebral blood flow and its impact on HIE has 
yet to be reached. Furthermore, these molecules have also 
been associated with BBB breakdown as well as the exci-
totoxic damage noted in HIE. The huge potential of EPC 
therapy has to be balanced with a need for the in-depth 
study of its potential risks and the harmful contributions 
it may make to the pathways of HI injury.
 Conclusion 
 In this review, we started with our understanding of 
the structure and function of the BBB. We went on to dis-
cuss the effects of HI injury of the immature brain on the 
BBB, and finally we touched on exciting therapeutic op-
tions linked to the targeting of the BBB, including MTH 
technology and stem cell therapy. These developments 
offer new hope for the improved management of HIE in 
the future.
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